Kumaraguru Raja
Stock Analyst at Brookline Capital
(n/a)
# 4,377
Out of 4,829 analysts
15
Total ratings
11.11%
Success rate
-53.64%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kumaraguru Raja
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QNCX Quince Therapeutics | Initiates: Buy | $9 | $1.01 | +791.09% | 1 | Dec 18, 2024 | |
| PALI Palisade Bio | Initiates: Buy | $38 | $0.76 | +4,900.00% | 1 | Nov 20, 2024 | |
| SABS SAB Biotherapeutics | Initiates: Buy | $8 | $1.97 | +306.92% | 1 | Jun 7, 2024 | |
| FBRX Forte Biosciences | Initiates: Buy | $100 | $6.91 | +1,347.18% | 2 | May 30, 2024 | |
| HEPA Hepion Pharmaceuticals | Downgrades: Hold | n/a | $0.40 | - | 1 | Dec 7, 2023 | |
| OTLK Outlook Therapeutics | Downgrades: Hold | n/a | $1.57 | - | 1 | Aug 30, 2023 | |
| ADIL Adial Pharmaceuticals | Reiterates: Buy | $150 | $0.61 | +24,587.29% | 2 | Jul 11, 2023 | |
| GNTA Genenta Science | Assumes: Buy | $15 | $4.25 | +252.94% | 1 | Jun 29, 2023 | |
| RAIN Rain Enhancement Technologies Holdco | Reinstates: Buy | $21 | $8.30 | +153.01% | 1 | Jan 31, 2023 | |
| MNPR Monopar Therapeutics | Reinstates: Buy | $90 | $36.03 | +149.79% | 1 | Dec 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $31 | $0.53 | +5,716.14% | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $3,360 | $0.79 | +425,162.62% | 1 | Sep 21, 2021 |
Quince Therapeutics
Dec 18, 2024
Initiates: Buy
Price Target: $9
Current: $1.01
Upside: +791.09%
Palisade Bio
Nov 20, 2024
Initiates: Buy
Price Target: $38
Current: $0.76
Upside: +4,900.00%
SAB Biotherapeutics
Jun 7, 2024
Initiates: Buy
Price Target: $8
Current: $1.97
Upside: +306.92%
Forte Biosciences
May 30, 2024
Initiates: Buy
Price Target: $100
Current: $6.91
Upside: +1,347.18%
Hepion Pharmaceuticals
Dec 7, 2023
Downgrades: Hold
Price Target: n/a
Current: $0.40
Upside: -
Outlook Therapeutics
Aug 30, 2023
Downgrades: Hold
Price Target: n/a
Current: $1.57
Upside: -
Adial Pharmaceuticals
Jul 11, 2023
Reiterates: Buy
Price Target: $150
Current: $0.61
Upside: +24,587.29%
Genenta Science
Jun 29, 2023
Assumes: Buy
Price Target: $15
Current: $4.25
Upside: +252.94%
Rain Enhancement Technologies Holdco
Jan 31, 2023
Reinstates: Buy
Price Target: $21
Current: $8.30
Upside: +153.01%
Monopar Therapeutics
Dec 9, 2022
Reinstates: Buy
Price Target: $90
Current: $36.03
Upside: +149.79%
May 18, 2022
Maintains: Buy
Price Target: $29 → $31
Current: $0.53
Upside: +5,716.14%
Sep 21, 2021
Initiates: Buy
Price Target: $3,360
Current: $0.79
Upside: +425,162.62%